| Outcome Measures: |
Primary: Change from baseline in the secretion of cytokines/adipokines by adipose tissue, The primary objective is to determine whether 6 weeks of treatment with saxagliptin, compared to placebo, causes a reduction from baseline in the production and secretion of cytokines/adipokines by adipose tissue, 6 weeks | Secondary: reduction from baseline in tissue measures of inflammation, The secondary objective is to determine whether 6 weeks of treatment with saxagliptin, compared to placebo, causes a reduction from baseline in reactive oxygen production, pro-inflammatory gene expression, toll-like receptor and nuclear factor-kappa B activation, and macrophage infiltration in adipose tissue of obese individuals, 6 weeks|change in plasma postprandial lipids, We will also compare the change in postprandial lipids following a standard meal between placebo and saxagliptin, 6 weeks|change in reactive hyperemic index, We will use peripheral artery tonometry to measure the change in endothelial function by measuring reactive hyperemic index, 6 weeks | Other: change in percent arteriole dilation, Using arterioles isolated from tissue biopsies, we will measure dose related responses to distinct dilators, 6 weeks
|
